| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
A QI evaluation of a Butterfly-enabled POCUS program—centered on lung ultrasound for pulmonary congestion and assisted by an AI B-line Counter—was associated with 246 bed-days freed and $751,537 in direct cost savings in admissions for undifferentiated dyspnea, including acute heart-failure exacerbations.
Butterfly Network, Inc. (NYSE:BFLY), a digital health company transforming care through portable, semiconductor-based ultrasound technology and intuitive software, today announced that the full results of the POCUS for Cardiopulmonary Assessment and Resource Evaluation (POCUS-CARE) trial have been published in The Journal of the American Medical Association (JAMA).
The study, led by researchers at Rutgers Robert Wood Johnson Medical School (RWJMS) and supported by Butterfly Network, found that integrating a hospitalist POCUS workflow—heavily focused on lung ultrasound (LUS) for pulmonary congestion and assisted by an FDA-cleared Auto B-line Counter—together with focused cardiac views into the routine assessment of adults admitted with undifferentiated dyspnea was associated with shorter length of stay and lower direct hospitalization costs. In this six-month stepped-wedge quality-improvement (QI) evaluation that reached 208 patients, the collaborative model (hospitalists with sonographer mentoring and remote cardiologist support) was associated with 246 hospital bed-days saved and $751,537 in direct cost savings.
Key findings from the study include:
Posted In: BFLY